AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.12 | KE:149 | Increase, Inflammation |
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.17 | KE:768 | Increase, Cytotoxicity |
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.2 | KE:149 | Increase, Inflammation |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.14 | KE:768 | Increase, Cytotoxicity |
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.25 | KE:155 | Inadequate DNA repair |
AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.17 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.5 | KE:1154 | Increased, Triiodothyronine (T3) in tissues |
KE:1829 | Altered, Thyroid hormone-dependent gene expression |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:149 | Increase, Inflammation |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.29 | KE:155 | Inadequate DNA repair |
KE:1636 | Increase, Chromosomal aberrations |
AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal System Disease; Respiratory System Disease | - | 0.14 | KE:149 | Increase, Inflammation |
AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine System Disease | - | 0.12 | KE:1614 | Decrease, androgen receptor activation |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.14 | KE:1669 | Increased, DNA damage and mutation |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.2 | KE:155 | Inadequate DNA repair |
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.2 | KE:1770 | Decrease, Mitochondrial membrane potential |
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.11 | KE:1793 | Activator protein 1 activation |
AOP:362 | Immune mediated hepatitis | Gastrointestinal System Disease; Immune System Disease | - | 0.12 | KE:1633 | Increase in inflammation |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.12 | KE:1770 | Decrease, Mitochondrial membrane potential |
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.12 | KE:1669 | Increased, DNA damage and mutation |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1669 | Increased, DNA damage and mutation |
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.2 | KE:1669 | Increased, DNA damage and mutation |
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.09 | KE:155 | Inadequate DNA repair |
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.11 | KE:149 | Increase, Inflammation |
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.05 | KE:149 | Increase, Inflammation |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.11 | KE:1669 | Increased, DNA damage and mutation |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.11 | KE:2043 | Decrease, Sonic Hedgehog second messenger production |
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.09 | KE:149 | Increase, Inflammation |
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.11 | KE:149 | Increase, Inflammation |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.2 | KE:155 | Inadequate DNA repair |
KE:1636 | Increase, Chromosomal aberrations |
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.17 | KE:2043 | Decrease, Sonic Hedgehog second messenger production |
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.1 | KE:1633 | Increase in inflammation |
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.2 | KE:149 | Increase, Inflammation |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.08 | KE:1656 | Antagonism, Thyroid Receptor |
AOP:531 | VEGFR inhibition leading to Keratinocyte differentiation-associate Hand-foot skin reaction | Unclassified | - | 0.12 | KE:11005 | Hyperkeratosis |
AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous System Disease | - | 0.17 | KE:149 | Increase, Inflammation |